semaglutide law 🚨 FDA Ends Shortage The FDA has officially declared an end to the shortage of semaglutide, the active ingredient in the popular medications Ozempic and Wegovy. This announcement signals a significant 🚨 FDA Ends Semaglutide Shortage

The 2nd GLP-1-Based Therapeutics Summit returns to tackle the challenges in best-in-class GLP-1 development and indication expansion with new clinical data, new preclinical data, and 18+ expert speakers including Eli Lily, Regeneron, Roche, Novo Nordisk, Fractyl Health and more at the forefront of the field

GLP1R-positive medullary thyroid carcinomas and all benign insulinomas are candidates for in vivo GLP1R targeting.

Discover our extensive range

While generally well tolerated, GLP-1RAs have been associated with gastrointestinal side effects, including rare reports of bowel obstruction

I could have kept this a secret